Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01972568 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase 2 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 2
- Development phase
- 306
- Enrollment target
NCT01972568 is a Phase 2 study that has completed, run by EMD Serono. The registered enrollment target is 306 participants.
The verdict
NCT01972568, a Phase 2 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 306 participants
- Enrollment target
Study Summary
This is a multi-center, double-blind, randomized, Phase 2b trial to evaluate the efficacy of atacicept in subjects with systemic lupus erythematosus (SLE).
Interventions
- DRUG Placebo
- DRUG Atacicept 150 mg
- DRUG Atacicept 75 milligram (mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01972568
The ClinicalTrials.gov registry entry for NCT01972568 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01972568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01972568 about?
NCT01972568 is a clinical study titled "Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus". This is a multi-center, double-blind, randomized, Phase 2b trial to evaluate the efficacy of atacicept in subjects with systemic lupus erythematosus (SLE).
What is the current status of trial NCT01972568?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 306 participants. The study started on 2013-12. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01972568?
The interventions under investigation include: Placebo (DRUG), Atacicept 150 mg (DRUG), Atacicept 75 milligram (mg) (DRUG).
Who is sponsoring clinical trial NCT01972568?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.